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Effect of Vaginal Mesh Hysteropexy vs Vaginal Hysterectomy
With Uterosacral Ligament Suspension on Treatment Failure
inWomenWith Uterovaginal Prolapse
A Randomized Clinical Trial
Charles W. Nager, MD; Anthony G. Visco, MD; Holly E. Richter, PhD, MD; Charles R. Rardin, MD; Rebecca G. Rogers, MD; Heidi S. Harvie, MD, MSCE, MBA;
Halina M. Zyczynski, MD; Marie Fidela R. Paraiso, MD; DonnaMazloomdoost, MD; Scott Grey, PhD; Amaanti Sridhar, MS; Dennis Wallace, PhD;
for the NICHD Pelvic Floor Disorders Network
IMPORTANCE Vaginal hysterectomywith suture apical suspension is commonly performed for
uterovaginal prolapse. Transvaginal mesh hysteropexy is an alternative option.
OBJECTIVE To compare the efficacy and adverse events of vaginal hysterectomywith suture
apical suspension and transvaginal mesh hysteropexy.
DESIGN, SETTING, PARTICIPANTS At 9 clinical sites in the US Pelvic Floor Disorders Network,
183 postmenopausal womenwith symptomatic uterovaginal prolapse were enrolled in a
randomized superiority clinical trial between April 2013 and February 2015. The study was
designed for primary analysis when the last randomized participant reached 3 years of
follow-up in February 2018.
INTERVENTIONS Ninety-three womenwere randomized to undergo vaginal mesh
hysteropexy and 90were randomized to undergo vaginal hysterectomywith uterosacral
ligament suspension.
MAINOUTCOMES ANDMEASURES The primary treatment failure composite outcome
(re-treatment of prolapse, prolapse beyond the hymen, or prolapse symptoms)was evaluated
with survival models. Secondary outcomes included operative outcomes and adverse events,
andwere evaluatedwith longitudinal models or contingency tables as appropriate.
RESULTS A total of 183 participants (mean age, 66 years) were randomized, 175 were
included in the trial, and 169 (97%) completed the 3-year follow-up. The primary outcome
was not significantly different among womenwho underwent hysteropexy vs hysterectomy
through 48months (adjusted hazard ratio, 0.62 [95% CI, 0.38-1.02]; P = .06; 36-month
adjusted failure incidence, 26% vs 38%). Mean (SD) operative time was lower in the
hysteropexy group vs the hysterectomy group (111.5 [39.7] min vs 156.7 [43.9] min;
difference, −45.2 [95% CI, −57.7 to −32.7]; P = <.001). Adverse events in the hysteropexy
vs hysterectomy groups includedmesh exposure (8% vs 0%), ureteral kinking managed
intraoperatively (0% vs 7%), granulation tissue after 12 weeks (1% vs 11%), and suture
exposure after 12 weeks (3% vs 21%).
CONCLUSIONS AND RELEVANCE Amongwomenwith symptomatic uterovaginal prolapse
undergoing vaginal surgery, vaginal mesh hysteropexy compared with vaginal hysterectomy
with uterosacral ligament suspension did not result in a significantly lower rate of the
composite prolapse outcome after 3 years. However, imprecision in study results
precludes a definitive conclusion, and further research is needed to assess whether
vaginal mesh hysteropexy is more effective than vaginal hysterectomywith uterosacral
ligament suspension.
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S urgery foruterovaginalprolapse is common. Inananaly-sis of aUSdatabase from2007 to2011, an estimated 13%of women underwent pelvic organ prolapse surgery by
theageof80years.1 In a2016BritishSocietyofUrogynecology
survey with a 42% response rate, 75% of 212 urogynecology
surgeons considered vaginal hysterectomy the procedure
of choice for women with uterovaginal prolapse.2 Uterine-
sparing suspension techniques, known as hysteropexy, are in-
creasing in usage, but in a US inpatient hospital database from
2002 to 2012, hysteropexy accounted for 5% of uterovaginal
prolapse procedures and hysterectomies were performed 8
timesmore often.3 In a survey of 244 US womenwith an 89%
response rate, 36% preferred uterine preservation, 20% pre-
ferredhysterectomy,and44%wereambivalentassumingcom-
parable outcomes at the time of uterovaginal prolapse repair.4
Thebroad rangeof age, goals, andexpectationsofwomenwho
seekprolapsesurgicalcorrectionandtheelectivenatureof treat-
ment are ideallyweighed in a shared decision-making process
grounded in sound scientific evidence.
A2016Cochrane reviewof trials comparing apical suspen-
sions for management of uterovaginal prolapse found that no
conclusion could be reached regarding superiority of uterine-
preservingsurgeryusingmeshreinforcementvssurgicalproce-
dures including vaginal hysterectomy.5 Although transvaginal
meshproceduresarecontroversial, fewhigh-quality, long-term
data compare apical transvaginalmeshwith native tissue pro-
ceduresandboth theUSFoodandDrugAdministrationandthe
UKNational InstituteforHealthandCareExcellencerecommend
further research on transvaginalmesh procedures.6
To address this evidence gap, the Study of Uterine Pro-
lapse Procedures Randomized Trial (the SUPeR trial) was de-
signed to compareeffectiveness andadverse eventsof 2 trans-
vaginal apical suspension strategies foruterovaginal prolapse:
mesh-augmentedhysteropexyandvaginalhysterectomywith
suture apical suspension.
Methods
Study Design and Procedures
This 9-center, randomized, superiority trial, with enrollment
fromApril 2013 toFebruary2015 and follow-upuntil February
2018, comparedanatomic and functional outcomes inwomen
with uterovaginal prolapse after a vaginal mesh hysteropexy
(hysteropexy) or a vaginal hysterectomywithuterosacral liga-
ment vault suspension (hysterectomy). The study was con-
ducted by the Eunice Kennedy Shriver National Institute of
ChildHealthandHumanDevelopment–sponsoredPelvicFloor
Disorders Network. The trial design has been published in
detail7 and the protocol and statistical analysis plan can be
found in Supplement 1. The senior statistician (D.W.) re-
mained masked through June 13, 2018, before which all sub-
stantive revisions to the statistical analysis plan were made.
Theprotocolwas approvedbyan independentdata and safety
monitoringboardassembledbytheEuniceKennedyShriverNa-
tional Institute of ChildHealth andHumanDevelopment and
institutional review boards at each site. Participants pro-
vided written informed consent.
Study Population
Eligible participants includedwomen aged at least 21 years re-
questing vaginal surgery for symptomatic uterovaginal pro-
lapse beyond thehymen. Participantswere amenorrheic for at
least 1 year to allowmasking, had completed childbearing, and
had uterine descent into the lower half of the vagina. Women
with prior uterine suspensions, prior synthetic grafts for pro-
lapse repair, oruterine abnormalitieswere excluded (Figure 1).
Detailed inclusionandexclusioncriteriaareprovided inSupple-
ment 1. For study generalizability and inclusivity, all races/
ethnicitieswere included;participants self-classified their race/
ethnicity with options defined by the investigator.
Randomization
Participants consented to remainingmasked to treatment as-
signment for the study duration unless a medical indication
for unmasking was identified. Participants were randomized
1:1 in the operating room with an automated web-based sys-
tem using permuted blocks with block sizes of 2 or 4 strati-
fied by site.8 Concomitant native tissue vaginal prolapse re-
pairs, such as anterior or posterior repairs, perineal
reconstruction, and full-length mesh midurethral slings for
stress urinary incontinence, were permitted.
Interventions
Surgeon certification required performance of at least 5 recent
procedures of each intervention; surgery standardization can
be found in the protocol in Supplement 1. Briefly, hysteropexy
wasstandardizedwith theUpholdLITEtransvaginalmeshsup-
portsystem(BostonScientific)andtheuterosacral ligamentsus-
pension required 1permanent and 1delayedabsorbable suture
on each side (eFigures 1 and 2 in Supplement 2).
Outcomes
Operative and perioperative outcomeswere captured on pre-
specified case report forms and included planned and per-
formed concomitant procedures, operative time, estimated
blood loss, number and types of sutures used, a Pelvic Organ
Key Points
Question Is there a difference in treatment failure for vaginal
mesh hysteropexy vs vaginal hysterectomywith uterosacral
ligament suspension in womenwith uterovaginal prolapse?
Findings In this randomized clinical trial that included 175
postmenopausal womenwith symptomatic uterovaginal prolapse
undergoing surgical intervention, vaginal mesh hysteropexy
compared with vaginal hysterectomywith uterosacral ligament
suspension resulted in a hazard ratio for a composite measure of
treatment failure of 0.62 after 3 years. This was not statistically
significant, but the CI was wide and the P value was .06.
Meaning Although vaginal mesh hysteropexy did not result in a
statistically significantly better outcome compared with vaginal
hysterectomywith uterosacral ligament suspension, the wide CI
for the treatment effect precludes a definitive conclusion, and
further research is needed to assess whether vaginal mesh
hysteropexy is more effective than vaginal hysterectomywith
uterosacral ligament suspension.
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ProlapseQuantification (POP-Q)9examinationat theendof the
procedure, andanadverse event report formthat includedan-
esthesia complications and a comprehensive medical, surgi-
cal, and organ injury survey. A hospital stay case report form
Figure 1. Participants in a Study of the Effect of Vaginal Mesh Hysteropexy vs Vaginal Hysterectomy on
Treatment Failure inWomenWith Uterovaginal Prolapse
1768 Patients screened for eligibility
213 Eligible patients consented
1555 Patients excluded
444 Not eligible
211 Concern with hysteropexy
89 Adherence issue
72 Other randomization concern
8 Other
396 Decided on an alternative
surgical procedure
335 Concern with hysterectomy
30 Patients were not randomized
16 Withdrew consent
4 Not eligible
3 Investigator withdrew
3 Lost to follow-up
2 Recruitment limit reached
1 Canceled surgery
1 Insurance changed
183 Patients randomized
1 Participant died during follow-up
at 12-24 months
87 Participants completed follow-up
at 12-24 months
2 Participants lost to follow-up
at 12-24 months
1 Died
1 Withdrew
84 Participants completed follow-up
at 12-24 months
88 Participants included in the primary
analysis
5 Participants were ineligible for
inclusion in the primary analysis
87 Participants included in the primary
analysis
3 Participants were ineligible for
inclusion in the primary analysis
1 Participants withdrew from the study
during follow-up at 36-48 months
11 Participants pending completion of
follow-up at 42 months
33 Participants completed follow-up
at 42 months
40 Participants completed follow-up
at 48 months
2 Participants withdrew from the study
during follow-up at 36-48 months
1 Participant was lost to follow-up
at 36-48 months
9 Participants pending completion of
follow-up at 42 months
35 Participants completed follow-up
at 42 months
37 Participants completed follow-up
at 48 months
88 Participants completed follow-up
at 0-12 months
1 Participant died during follow-up
at 0-12 months
86 Participants completed follow-up
at 0-12 months
2 Participants withdrew from the study
during follow-up at 24-36 months
85 Participants completed follow-up
at 24-36 months
84 Participants completed follow-up
at 24-36 months
90 Patients randomized to undergo hysterectomy
87 Received intervention as randomized
3 Received intervention as randomized but
were found ineligible for the intervention
2 During review of initial POP-Q
1 During review of initial PFDI-20
93 Patients randomized to undergo hysteropexy
88 Received intervention as randomized
5 Received intervention as randomized but
were found ineligible for the intervention
during review of initial POP-Q
Perforated colonic diverticulumwas
the cause of death for the participant
lost to follow-up in the hysterectomy
group at 0-12 months, lung cancer
was the cause of death for the
participant in the hysteropexy group
during follow-up at 12-24months,
and leukemia was the cause of death
for the participant in the
hysterectomy group during follow-up
at 12-24months. POP-Q indicates
Pelvic Organ Prolapse Quantification;
PFDI, Pelvic Floor Distress Inventory.
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included blood transfusions, intensive care unit admissions,
postoperative tests, lengthof catheterization, andasecondad-
verse event survey.
Study visitswere conducted at 6-month intervalswith all
participants, including thosewhoexperienced treatment fail-
ure and/or re-treatment. Study personnel masked to treat-
mentassignmentadministered thepatientquestionnaires and
the comprehensive 5-page adverse event survey. The pelvic
examination for prolapse assessment, suture, and mesh ex-
posure was performed by a clinician other than the surgeon.
At each visit, participants were queried about their knowl-
edge of their treatment allocation.
The primary outcome was a composite measure of treat-
ment failure that included any of the following: (1) re-
treatment for prolapse (pessary fitting or surgery); (2) ana-
tomic outcomes, defined as any POP-Q9measure beyond the
hymen; and (3) symptomatic outcomes, defined as a positive
response (and any degree of bother other than “not at all”) to
the Pelvic Floor Distress Inventory10 question “Do you usu-
ally have a bulge or something falling out that you can see or
feel in your vaginal area?”
Secondary outcomes included groupdifferences in opera-
tive and perioperative outcomes; individual anatomic mea-
suresof thePOP-Qexamination;andpresence, severity, andef-
fectofprolapse,urinary,bowel,andpainsymptomsasmeasured
by the Pelvic Floor Distress Inventory,11 Patient Global Impres-
sion of Improvement,10 Incontinence Severity Index,12 Pelvic
Floor Impact Questionnaire,11 Functional Activity Scale,13 and
surgical pain and body part pain scales.14 Sexual functionwas
assessed with the Pelvic Organ Prolapse/Incontinence Sexual
FunctionQuestionnaire, IUGA-Revised(PISQ-IR)15andbodyim-
age was assessed using the body image scale.16,17
Sample Size Calculation
The study was designed as a superiority trial. The hysterec-
tomy group was assumed to have a failure risk of 20% at 24
months, based on 15% anatomic failure and an additional 5%
symptomfailure.18A2012hysteropexystudy reporteda2%12-
monthanatomicfailurerisk,19whichcorrespondstoa2-yearrisk
of 4%, assuming a constant hazard.Adding a similar estimated
symptom failure suggested that the hysteropexy groupwould
have a 2-year failure risk in the range of 7% to 10%. The corre-
spondingbetween-groupdifference in failure riskof 10%to13%
wasconsideredclinicallymeaningful.Theplanned180partici-
pantswereoriginally estimated toprovidepowerof0.89 tode-
tect a risk difference of 10% (10% failure for the hysteropexy
groupvs20%failure for thehysterectomygroup)at2years, cor-
responding to a hazard ratio of 0.47 assuming an exponential
failure distribution. However, after all participants completed
at least 4 years of follow-up, an error was found in the original
sample size calculation, and the planned 180 participants ac-
tuallyprovidedapowerof0.86todetecta riskdifferenceof 12%
(8%failure for thehysteropexygroupvs20%failure for thehys-
terectomy group) at 2 years (eTable 5 in Supplement 2).
Statistical Analysis
Primary and secondary efficacy analyses were performed on
all randomized, eligible patients; safety analyses and second-
ary sensitivity analyses were performed on all randomized
participants. All analyses were based on a statistical analysis
plan prepared by a masked statistician with all analytic deci-
sions based on masked data reviews. The analysis was
planned to occur when the last participant reached 3 years of
follow-up. The significance level for the primary analysis was
set at α = .047 to account for an interim analysis conducted
at α = .009 after the last participant reached 2 years of follow-
up. Because all analyses other than the primary analysis are
considered exploratory or supportive, CIs and P values are
descriptive with no adjustments for multiple comparisons.
Analyses were performed using SAS software, version 9.4 or
higher (SAS Institute).
Primary superiority analyses used a proportional hazard
survival model to account for interval-censored data and an
aggregate time-varying hazard. The piecewise exponential
baseline hazard specified 4 constant-hazard periods (0-12
months, 12-24months, 24-36months, and >36months), was
determined by masked review of the aggregate survival dis-
tribution, and controlled for site consistent with study ran-
domization and prior prolapse surgery per clinical standards.
Sensitivity analyseswere conductedwithout covariate adjust-
ment,usingnonparametricmaximumlikelihoodestimation,20
andon the full randomizedpopulationwith the samepropor-
tional hazard model. Individuals who withdrew or were lost
to follow-up were treated as randomly censored.
To account for missed visits and early discontinuations,
linearandgeneralized linearmixedmodelswereused toevalu-
ate changes from baseline to 12, 24, and 36 months for sec-
ondary continuous and binary outcomes measured longitu-
dinally,with site included in themodels as a covariate andvisit
time treated as a categorical measure. Differences between
treatmentgroups for time-specificmeasuresof composite fail-
ure and aggregate binary measures of efficacy and adverse
eventswere assessedwithMantel-Haenszel tests stratified by
site, standard χ2 tests, or Fisher exact tests, while differences
in other continuous measures were evaluated with t tests.
Results
Study Population, Group Assignments, and Treatment
Between April 2013 and February 2015, 183 women were ran-
domized (93 in the hysteropexy group and 90 in the hysterec-
tomygroup) at 9 sites by 34 female pelvicmedicine and recon-
structive surgery subspecialists. The primary analysis was
performedwhenthelastrandomizedparticipantreached3years
of follow-up in February 2018. Eight participants deemed in-
eligible on masked data review were excluded from the pri-
mary analysis. Of the 175 randomized participants eligible for
inclusion in theprimary analysis, 6discontinuedparticipation
at or prior to 36months and 153 attended their 36-month visit
(Figure 1).Missed6-month interval follow-upvisits through36
months ranged from 1.2% to 9.5%. Missing data were treated
asmissing at random.Baseline demographic and clinical char-
acteristics were similar between the groups (Table 1).
Concomitant retropubic midurethral slings were per-
formedon29of88women(33%) in thehysteropexygroupand
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Table 1. Participant Baseline Characteristics in a Study of the Effect
of Vaginal Mesh Hysteropexy vs Vaginal Hysterectomy on Treatment
Failure inWomenWith Uterovaginal Prolapse
Characteristic
Treatment Group, No. (%)a
Hysteropexy
(n = 88)
Hysterectomy
(n = 87)
Age, mean (SD), y 65.5 (7.3) 66.2 (7.4)
Race
White 73 (83) 77 (89)
Black 8 (9) 3 (3)
American Indian/
Alaskan Native
0 4 (5)
Asian 2 (2) 1 (1)
More than 1 0 1 (1)
Other 5 (6) 1 (1)
Hispanic or Latina,
No./total (%)
9/85 (11) 7/85 (8)
Marital status
Married/living with partner 56 (64) 58 (67)
Single 9 (10) 7 (8)
Divorced/separated 16 (18) 13 (15)
Widowed 7 (8) 9 (10)
Education (n = 86) (n = 85)
Less than high school 6 (7) 5 (6)
High school/GED 31 (36) 26 (31)
Associate college degree 22 (26) 19 (22)
4-y college degree 16 (19) 20 (24)
Graduate degree 11 (13) 15 (18)
Health insurance
Medicaid/Medicare 48 (55) 51 (59)
Private 36 (41) 33 (38)
Other 4 (5) 3 (3)
Medical history
Gravidity, median (IQR) 3 (2-5) 3 (2-4)
Parity, median (IQR) 3 (2-3) 2 (2-3)
BMI, mean (SD) 28.9 (4.0) 28.2 (4.4)
Postmenopausal 86 (98) 85 (98)
History of smoking 22 (25) 21 (24)
Current smoker 3 (3) 1 (1)
Prior stress urinary incontinence
surgery
4 (5) 4 (5)
Prior pelvic organ prolapse
surgery
5 (6) 4 (5)
Other prior pelvic
surgery
42 (48) 43 (49)
Duration of pelvic organ
prolapse symptoms,
median (IQR), mo
26 (11-56) 33 (12-58)
POP-Q measurement,
mean (SD), cmb
Ba 3.3 (2.0) 3.0 (2.2)
Bp 0.4 (3.0) 0.7 (3.0)
C 0.4 (3.5) 0.7 (3.6)
TVL 9.1 (1.1) 9.1 (1.1)
POP-Q stagec
2 15 (17) 19 (22)
3 63 (72) 59 (68)
4 10 (11) 9 (10)
Postvoid residual, mL (n = 88) (n = 86)
Median (IQR) 40 (10-80) 30 (7-80)
(continued)
Table 1. Participant Baseline Characteristics in a Study of the Effect
of Vaginal Mesh Hysteropexy vs Vaginal Hysterectomy on Treatment
Failure inWomenWith Uterovaginal Prolapse (continued)
Characteristic
Treatment Group, No. (%)a
Hysteropexy
(n = 88)
Hysterectomy
(n = 87)
Patient-reported outcome scores, mean (SD)
Pelvic Floor Distress Inventoryd 112.9 (56.9) 109.5 (50.0)
Pelvic Organ Prolapse Distress Inventoryd 49.1 (23.6) 47.8 (21.0)
Urogenital Distress Inventoryd 42.5 (26.0) 38.3 (26.5)
Colorectal Anal Distress Inventoryd 21.3 (21.1) 23.3 (18.3)
Pelvic Floor Impact Questionnairee 57.5 (59.6) 56.8 (58.5)
Pelvic Organ Prolapse Impact Questionnairee 18.7 (24.8) 20.9 (22.0)
Urinary Impact Questionnairee 27.6 (27.2) 22.8 (27.8)
Colorectal Anal Impact Questionnairee 11.2 (20.4) 13.2 (20.8)
Incontinence Severity Indexf 4.6 (4.2) 3.5 (3.5)
Functional Activity Scaleg 88.8 (15.1) 87.7 (16.5)
Surgical pain scaleh 1.8 (2.4) 1.9 (2.3)
Body part pain scalei 0.9 (1.1) 0.8 (1.1)
Body image scalej 6.4 (6.4) 5.3 (6.0)
PISQ-IR score of sexually active womenk (n = 30) (n = 40)
Mean (SD) 3.0 (0.5) 2.9 (0.4)
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); GED, general educational development;
IQR, interquartile range; ISI, Incontinence Severity Index; PISQ-IR, Pelvic Organ
Prolapse/Incontinence Sexual Function Questionnaire, IUGA-Revised;
POP-Q, Pelvic Organ Prolapse Quantification; TVL, total vaginal length.
a Sample size is 88 for the hysteropexy group and 87 for the hysterectomy
group unless otherwise specified.
b TheTVL fromtheposterior fornix to thehymenwhenPOP-QpointC is reduced to
its full normalposition.POP-QpointC representseither themostdistal edgeof the
cervixorthe leadingedgeofthevaginalcuff (hysterectomyscar);pointBp,themost
distal positionof anypart of theupperposterior vaginalwall andhas a rangeof
−3.0 cmtoTVL; pointBa, themostdistal positionof anypart of theupper anterior
vaginalwallandhasarangeof−3.0cmtoTVL.Patientswithoutpelvicorganprolapse
havenegative values. See eFigure 3 in Supplement 2 for additional information.
c POP-Q stage 2 indicates that the vagina is prolapsed between 1 cm above and
1 cm below the hymen; stage 3, the vagina is prolapsedmore than 1 cm beyond
the hymen but is not everted within 2 cm of its length; stage 4, the vagina is
everted to within 2 cm of its length.
d The Pelvic Floor Distress Inventory score ranges from0 (least distress) to 300
(most distress) and is a sum of the 3 subscale scores (Pelvic Organ Prolapse
Distress Inventory, Urogenital Distress Inventory, and Colorectal Anal Distress
Inventory), each ranging from0 (least distress) to 100 (most distress).
e The Pelvic Floor Impact Questionnaire score ranges from0 (least impact) to
300 (most adverse impact) and is a sum of 3 subscale scores (Pelvic Organ
Prolapse Impact Questionnaire, Urinary Impact Questionnaire, and Colorectal
Anal Impact Questionnaire), each ranging from0 (least impact) to 100 (most
adverse impact). A midrange score for these subscales implies bother from
prolapse, urinary incontinence, or fecal incontinence.
f The ISI score ranges from0 (no incontinence) to 12 (severe incontinence) and
is a product of the frequency and volume of urine loss; a person losing small
splashes of urine a few times per week would score a 6.
g TheFunctionalActivityScalescorerangesfrom0to100,withhighervaluesindicating
better functional activity. Patientswhounderwent surgical hernia repairwith
independentdaily living andnocomorbidities have ameanvalueof80.13
h The surgical pain scale score for pain within the past 24 hours during normal
activities ranges from0 (no pain) to 10 (most intense pain).
i The body part pain scale score for mean pain in 7 different body areas within
the last 24 hours ranges from0 (no pain) to 10 (most intense pain).
j The body image scale score ranges from0 (no symptoms/distress) to 24 (severe
symptoms/distress). Amean score of 8 is typical in patientswith cancer.16
k PISQ-IRmean score ranges from 1 (worse sexual experience) to 5 (better sexual
experience).Midrange scores are common inwomenwithpelvic floor disorders.21
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31 of 87 (36%) in the hysterectomy group (difference, −0.03;
[95% CI, −0.17 to 0.11]) (eTable 1 in Supplement 2). Concomi-
tant transobturator midurethral slings were performed on 12
of88women (14%) in thehysteropexygroupand13of87 (15%)
in the hysterectomy group (difference, −0.01; [95% CI, −0.12
to0.09]) (eTable 1 in Supplement 2). Anterior repairwasmore
commonlyperformedonwomen in thehysteropexygroup (79
of 88 [90%]) than in the hysterectomy group (62 of 87 [71%])
(difference,0.19 [95%CI,0.07-0.30];P = .002).Mean (SD)op-
erative timewas lower in thehysteropexygroupcomparedwith
the hysterectomy group (111.5 [39.7] min vs 156.7 [43.9] min;
difference, −45.2 [95% CI, −57.7 to −32.7]; P < .001) (Table 2).
Primary Outcome
No statistically significant difference in failure risk was dem-
onstrated for thecompositeprimaryoutcomebetweengroups;
the adjusted hazard ratio of failure for hysteropexy vs hyster-
ectomy was 0.62 ([95% CI, 0.38-1.02]; P = .06) (Figure 2). At
36months, themodel-estimated failurewas26%(95%CI, 15%-
35%) for the hysteropexy group and 38% (95% CI, 25%-49%)
for thehysterectomygroup(Figure2). Sensitivityanalyseswith
nonparametric approaches,withoutcovariateadjustment, and
based on the full population yielded similar results (eFigures
4 and 5 in Supplement 2). The proportional hazards assump-
tion was violated when tested with a treatment × time inter-
action (P < .001). Graphical assessment (eFigure 6 in Supple-
ment 2) indicated that the smoothed failure hazard rate in the
hysterectomygroupwashigher than in thehysteropexygroup,
except fromapproximately 18 to 30months, duringwhich the
rates were similar. Therefore, the hazard ratio should be in-
terpreted as an average relative risk across time rather than a
relative risk applicable at all times.
Cumulative failures,noncumulative failurestatus, andfail-
ure categories at 12, 24, and 36months are shown in Table 3.
Failure rates basedon status at attendedvisits for both groups
are lower than that obtained from the survival (cumulative)
models that assumedpermanent failure. For example, the 36-
monthdiscrete timepoint failure rate forhysteropexywas21%
comparedwith26%estimatedfromthecovariate-adjustedsur-
vival model (33% observed); the failure rate for the hysterec-
tomy groupwas 27% comparedwith 38% estimated from the
adjusted survivalmodel (42%observed). Themajority of fail-
ureswere either anatomicor anatomic and symptomatic,with
few symptom-only failures.
Secondary Outcomes
Secondary outcomes at 36 months are shown in Table 2.
Mean (SD) postoperative anterior wall support (measured via
POP-Q point Ba) was better in the hysteropexy vs hysterec-
tomy group at 36 months (−1.2 [1.4] cm vs −0.7 [1.5] cm; dif-
ference,−0.5 [95%CI,−0.9 to0.0];P = .05)andmean (SD) total
vaginal length was longer in the hysteropexy vs hysterec-
tomy group (8.5 [1.1] cm vs 7.7 [1.2] cm; difference, 0.7 [95%
CI,0.4-1.1];P < .001).Ninetypercentofparticipants in thehys-
teropexy group and 89% in the hysterectomy group reported
“much better” or “very much better” improvement on the
Patient Global Impression of Improvement at 36months (risk
difference, 0.00 [95% CI, −0.09 to 0.10]; P = .93) and no
between-group differences were demonstrated in patient-
reported surgical pain, pelvic pain, or body image.
Seventy of 175 women (40%) were sexually active
before surgery (eTable 3 in Supplement 2). Sexual function
among the sexually active women, measured by the PISQ-IR
total score, improved by an adjusted mean of 0.3 points
(95% CI, 0.1-0.5) after surgery for both groups (adjusted
mean difference, 0.00 [95% CI, −0.2 to 0.3]; P = .84)
(Table 2). Dyspareunia prevalence rates among sexually
active women decreased from 10 of 26 women (38%) to 5 of
26 (19%) in the hysteropexy group and 17 of 37 (46%) to 5 of
31 (16%) in the hysterectomy group (eTable 3 in Supple-
ment 2). Any postoperative dyspareunia identified by spe-
cific complications or adverse events and the systematic
collection of open-ended adverse events throughout the
course of the trial occurred in 9 of 93 participants (10%) in
the hysteropexy group and 2 of 90 (2%) in the hysterectomy
group (risk difference, 0.07 [95% CI, 0.01-0.14]; P = .03). De
novo dyspareunia as measured by the PISQ-IR was only
recorded in 3 women in the hysterectomy group and 2 in the
hysteropexy group (Table 2).
At 36 months, 131 of 173 women (75%) reported that they
remained masked to their treatment, with no difference in
masking between groups (risk difference, 0.05 [95% CI,
−0.08 to 0.18]; P = .46) (Table 2). Of participants who stated
that they knew their treatment group, 26 of 30 (87%) were
correct, with no evidence of a between-group difference (risk
difference, −0.17 [95% CI, −0.47 to 0.10]; P = .29). The most
common sources of unmasking were insurance paperwork,
imaging studies, and conversations with physicians not
involved in the study.
Adverse Events
Ureteral “kinking” (7%) and midurethral sling mesh expo-
sures (5%) were only observed in the hysterectomy group
(Table 2). The hysteropexy group had an 8% mesh exposure
rate. Based on observations starting 12 weeks after the surgi-
cal procedure, granulation tissue and permanent suture ex-
posure were less common in the hysteropexy group than the
hysterectomy group (granulation tissue: 1% vs 11%; perma-
nent suture exposure: 3%vs21%).Nomeshexposures, granu-
lation tissue, or suture exposures required reoperation.Nopa-
tients in the hysteropexy group developed any significant
uterine pathology during the 3 years of follow-up. The most
common other adverse events for all 183 participants during
the3 to4yearsof follow-upwereurinary tract infections, stress
urinary incontinence, urgency incontinence, and constipa-
tion,withnoevidenceof between-groupdifferences (eTable4
in Supplement 2).
Discussion
Among women with symptomatic uterovaginal prolapse un-
dergoing vaginal surgery, vaginal mesh hysteropexy com-
paredwithvaginalhysterectomywithuterosacral ligamentsus-
pension did not result in a significantly lower rate of the
composite prolapse outcome after 3 years. However, because
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Table 2. Secondary Outcomes in a Study of the Effect of Vaginal Mesh Hysteropexy vs Vaginal Hysterectomy on Treatment Failure
inWomenWith Uterovaginal Prolapse
Outcome Hysteropexy (n = 88) Hysterectomy (n = 87)
Risk/Mean Difference
(95% CI)a P Valuea
Physical Examination at 36 Months
Pelvic Organ Prolapse Quantification
measurements, mean (SD)b
(n = 78) (n = 74)
Ba −1.2 (1.4) −0.7 (1.5) −0.5 (−0.9 to 0.0) .05
Bp −1.7 (1.5) −1.8 (1.3) 0.0 (−0.4 to 0.5) .84
C −5.7 (2.3) −5.8 (1.9) 0.1 (−0.6 to 0.8) .74
TVL 8.5 (1.1) 7.7 (1.2) 0.7 (0.4 to 1.1) <.001
POP-Q point C <−0.5 × TVL, No./total (%) 69/78 (88) 68/74 (92) −3 (−13 to 6) .48
Perioperative Outcomes
Operative time, min (n = 88) (n = 87)
Mean (SD) 111.5 (39.7) 156.7 (43.9) −45.2 (−57.7 to −32.7) <.001
Catheterization days (n = 87) (n = 85)
Median (IQR) 1 (1-3) 1 (1-3) .54
Ureteral kink recognized intraoperatively,
No./total (%)
0/88 6/87 (7) −7 (−15 to −2) .01
Postoperative Complications
Hysteropexy mesh exposurec
No./total (%) 7/88 (8)
Binomial, 95% CI, %d 3.3 to 15.7
Midurethral sling mesh exposure, No./total (%)c 0/41 2/44 (5) −5 (−15 to 5) .49
After 12 wk, No./total (%)c
Excessive granulation tissue 1/88 (1) 10/87 (11) −10 (−17 to −3) .005
Suture exposure 3/88 (3) 18/87 (21) −17 (−27 to −8) <.001
Patient-Reported Outcomes at 36 moe
PGII [much better or very much better],
No./total (%)f
70/78 (90) 67/75 (89) 0 (−9 to 10) .93
Pelvic Floor Distress Inventoryg (n = 78) (n = 75)
Adjusted mean (95% CI) −79.8 (−91.7 to −67.8) −80.1 (−92.3 to −67.8) 0.3 (−16.3 to 16.9) .97
POPDIg (n = 78) (n = 75)
Adjusted mean (95% CI) −40.1 (−45.2 to −35.0) −40.2 (−45.5 to −35.0) 0.1 (−7.0 to 7.2) .98
Urogenital Distress Inventoryg (n = 78) (n = 75)
Adjusted mean (95% CI) −28.3 (−34.2 to −22.4) −28.2 (−34.3 to −22.2) −0.0 (−8.2 to 8.2) >.99
CRADIg (n = 78) (n = 75)
Adjusted mean (95% CI) −11.4 (−15.6 to −7.2) −11.6 (−15.9 to −7.2) 0.2 (−5.7 to 6.1) .95
PFIQg (n = 78) (n = 75)
Adjusted mean (95% CI) −43.4 (−54.6 to −32.2) −50.4 (−61.9 to −38.8) 7.0 (−8.6 to 22.5) .38
POPIQg (n = 78) (n = 45)
No. 78 74
Adjusted mean (95% CI) −16.0 (−21.0 to −11.1) −19.9 (−25.0 to −14.8) 3.9 (−3.0 to 10.7) .27
Urinary Impact Questionnaireg (n = 78) (n = 75)
Adjusted mean (95% CI) −21.3 (−26.3 to −16.2) −20.6 (−25.8 to −15.4) −0.6 (−7.7 to 6.4) .86
CRAIQg (n = 78) (n = 74)
Adjusted mean (95% CI) −6.1 (−10.3 to −1.9) −9.8 (−14.1 to −5.5) 3.7 (−2.1 to 9.6) .21
Incontinence Survey Indexg (n = 78) (n = 75)
Adjusted mean (95% CI) −1.9 (−2.7 to −1.1) −1.6 (−2.5 to −0.8) −0.3 (−1.4 to 0.8) .60
New or worsening stress urinary incontinence,
No./total (%)c
18/88 (20) 12/87 (14) 7 (−4 to 18) .24
New or worsening urgency urinary incontinence,
No./total (%)c
21/88 (24) 14/87 (16) 8 (−4 to 20) .20
New or worsening fecal incontinence,
No./total (%), %c
13/88 (15) 6/87 (7) 8 (−1 to 17) .09
Functional Activity Scaleg (n = 78) (n = 75)
Adjusted mean (95% CI)g 5.6 (2.8 to 8.5) 4.8 (1.9 to 7.7) 0.8 (−3.1 to 4.8) .68
(continued)
Research Original Investigation Effect of Vaginal Mesh Hysteropexy vs Vaginal Hysterectomy inWomenWith Uterovaginal Prolapse
1060 JAMA September 17, 2019 Volume 322, Number 11 (Reprinted) jama.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of California - San Diego User  on 09/17/2019
Table 2. Secondary Outcomes in a Study of the Effect of Vaginal Mesh Hysteropexy vs Vaginal Hysterectomy on Treatment Failure
inWomenWith Uterovaginal Prolapse (continued)
Outcome Hysteropexy (n = 88) Hysterectomy (n = 87)
Risk/Mean Difference
(95% CI)a P Valuea
SPS-restg (n = 78) (n = 75)
Adjusted mean (95% CI) −0.5 (−1.0 to −0.1) −0.6 (−1.1 to −0.2) 0.1 (−0.5 to 0.7) .77
SPS-normalg (n = 78) (n = 75)
Adjusted mean (95% CI) −0.7 (−1.2 to −0.2) −0.7 (−1.2 to −0.2) −0.0 (−0.7 to 0.6) .97
SPS-exerciseg (n = 31) (n = 29)
Adjusted mean (95% CI) −1.2 (−2.0 to −0.5) −0.9 (−1.7 to −0.1) −0.4 (−1.5 to 0.7) .50
SPS-worstg (n = 75) (n = 74)
Adjusted mean (95% CI) −0.8 (−1.4 to −0.3) −0.5 (−1.1 to 0.0) −0.3 (−1.1 to 0.5) .47
Body part pain scale scoreg (n = 78) (n = 75)
Adjusted mean (95% CI) −0.5 (−0.7 to −0.3) −0.3 (−0.5 to −0.1) −0.2 (−0.5 to 0.1) .19
Pelvic pain, No./total (%)h 6/88 (7) 9/87 (10) −4 (−12 to 5) .40
All treated participants 6/93 (6) 9/90 (10) −4 (−12 to 4) .38
Daily 3/88 (3) 4/87 (5) −1 (−8 to 6) .72
Body image scale scoreg (n = 77) (n = 75)
Adjusted mean (95% CI) −4.9 (−6.1 to −3.7) −3.8 (−5.0 to −2.6) −1.1 (−2.7 to 0.6) .20
Sexual Function and Dyspareunia at 36 Months
PISQ-IR change from baseline of sexually activeg (n = 23) (n = 27)
Adjusted mean (95% CI) 0.3 (0.1 to 0.5) 0.3 (0.1 to 0.5) 0.0 (−0.2 to 0.3) .84
Dyspareunia, No./total (%)i
All treated participants 9/93 (10) 2/90 (2) 7 (1 to 14) .03
Sexually active with de novo dyspareunia
(PISQ-IR)
0/19 1/25 (4) −4 (−21 to 14) >.99
Not sexually active with de novo dyspareunia
(PISQ-IR)
2/38 (5) 2/27 (7) −2 (−20 to 12) >.99
Evaluation of Masking at 36 Months, No./Total (%)
Remained masked at 36 mo 68/88 (77) 63/87 (72) 5 (−8 to 18) .46
Correctly stated what procedure they underwentj 10/13 (77) 16/17 (94) −17 (−47 to 10) .29
Abbreviations: CRADI, Colorectal Anal Distress Inventory; CRAIQ, Colorectal Anal
Impact Questionnaire; PFIQ, Pelvic Floor Impact Questionnaire; PGII, Patient
Global Impression of Improvement; PISQ-IR, Pelvic Organ Prolapse/Incontinence
Sexual Questionnaire, IUGARevised; POPDI, Pelvic Organ Prolapse Distress
Inventory; POPIQ, Pelvic Organ Prolapse Impact Questionnaire; POP-Q, Pelvic
Organ ProlapseQuantification; SPS, surgical pain scale.
a Unless otherwise specified, mean differences, 95% CIs, and P values are
unadjusted and based on t tests for normally distributed continuous
outcomes, and P values for nonnormal continuous outcomes (summarized
with medians) are fromWilcoxon Rank Sum tests. Unless otherwise specified,
risk differences, 95% CIs, and P values are unadjusted and based on
Mantel-Haenszel estimates for the risk difference withWald-type CIs for
nominal categorical measures with expected cell counts >5, otherwise the
exact risk difference and 95% CI limits are obtained by exact methods based
on the score statistic based on Chan and Zhang22 and the P values are from
Fisher exact tests.
b For definitions of the Pelvic Organ Prolapse Quantificationmeasurements,
refer to footnote b in Table 1.
c Mesh exposure, excessive granulation tissue, suture exposure, new or
worsening stress urinary incontinence, urgency urinary incontinence, and fecal
incontinence are identified based on specific complications/adverse events
collected at follow-up visits at 6months through 5 years and the systematic
collection of open-ended adverse events throughout the trial.
d Binomial95%CIs forproportionsarebasedontheexactClopper-Pearsonmethod.
e The PGII score ranges from 1 (very much better) to 7 (very much worse) and
has been dichotomized as better (2) or worse (>2). Refer to Table 1 footnotes
for ranges and clinical interpretation of the other patient-reportedmeasures.
f Adjusted risk differences, 95% CIs, and P values comparing the proportions of
binary outcomes of the groups was planned to be obtained from generalized
linear models with identity link adjusted for site, intervention, visit, and
interaction between intervention and visit, while modeling the
within-participant correlations across visits as autoregressive order 1. This
specified adjustedmodel did not converge for the binary PGII response
(“much better” or “very much better” improvement), and unadjusted risk
difference at 36months was obtained.
g Adjustedmeans, mean difference, 95% CIs, and P values comparing the
change from baseline of continuous outcomes of the intervention groups are
obtained from general linear models adjusted for site, intervention, visit, and
interaction between intervention and visit, while modeling the
within-participant correlations across visits with an auto-regressive order 1.
The n shown is for month 36; however, models were fitted using all
participants with at least 1 postbaseline visit.
h Pelvic pain and daily pelvic pain occurring at least 12 weeks after surgical
intervention are identified based on both specific complications/adverse
events collected at follow-up visits at 6months through 5 years and the
systematic collection of open-ended adverse events throughout the trial.
i Dyspareunia is identified based on specific complications/adverse events
collected at 6-month through 5-year follow-up visits and the systematic
collection of open-ended adverse events throughout the course of the trial.
Sexually active with de novo dyspareunia (response of “usually” or “always
have” in response to the PISQ-IR question, “Do you have pain during sexual
intercourse?”) is defined as womenwhowere sexually active at baseline and at
3 years experiencing pain during sexual intercourse only at 3 years. Not
sexually active with de novo dyspareunia (PISQ-IR response of “strongly
agree” or “somewhat agree”) is defined as womenwhowere not sexually
active at baseline due to reasons other than fear of pain during sexual
intercourse and became sexually inactive at 3 years due to fear of pain during
sexual intercourse.
j Of the 24 women in the hysterectomy group and 20 in the hysteropexy group
who reported they had become unmasked, 7 in each group did not provide a
guess as to what procedure they underwent.
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the point estimate favored hysteropexy with a CI that was
wide and only slightly crossed the null value, the remaining
uncertainty is toogreat to either establishbenefit or to ruleout
the originally hypothesized magnitude of treatment effect.
While small differences in anterior prolapsemeasures and in-
creased vaginal length favored the mesh hysteropexy group,
these did not result in differences in patient-reported out-
come measures. Higher anterior repair rates in the hystero-
pexy group may account for the small improvements ob-
served in anterior prolapse support. The mesh exposure rate
of 8% was higher than previously reported for this hystero-
pexy technique,19,25 but congruent with rates reported after
vaginal surgery augmented withmesh.26,27 No exposures re-
quired surgical intervention.
Both groups reported improvements in sexual function,
anddyspareunia andpainanddenovodyspareunia rateswere
low.All other complicationswith long-termsequelaewerenot
different between groups.
While commonly performed at the time of a surgical
procedure for prolapse, hysterectomy is performed to allow
exposure to supporting ligaments, while possibly increasing
morbidity, such as infection and bleeding.28 The mean
operative time in the hysterectomy group was 45 minutes
longer than in the hysteropexy group, implying increased
risk and cost of this approach to prolapse repair for
unknown benefit. The findings are consistent with a 2018
systematic review of hysteropexy vs hysterectomy for pro-
lapse repair in which hysteropexy was favored in the short
term for decreased blood loss, shorter operative times, and
similar anatomic outcomes.29 None of the trials compared
mesh hysteropexy with hysterectomy with uterosacral liga-
ment suspension, and randomized trials involving suture
hysteropexy and vaginal hysterectomy have at most 12
months of follow-up.29-32
The current trial providesnew information for failure rate
ascertainment. The finding that failure rateswerehigherwith
a cumulative survival approach than at discrete time points
suggests that participants migrate across categorical defini-
tions of success and failure and questions the appropriate-
nessof theassumption thatwithprolapse surgery, “oncea fail-
ure, always a failure.” The dynamic aspect of prolapse is
supported by previous anatomic studies and should be con-
sidered in future studies.33 Failure rates for mesh hystero-
pexy in the current study were generally higher than antici-
patedandhigher thanthosereported inpreviouscohort studies
with shorter follow-up and less rigor in evaluation and failure
definition.19,25,34 Failure rates in this studyare consistentwith
the literatureonnative tissuevaginalprolapse repair.18Thedif-
ferences between the anticipated failure rates and the failure
rates in this study are attributable to theminimal literature on
hysteropexyoutcomeswhen this studywasdesigned, the cu-
mulative survival approach, the longer duration of follow-
up, and the rigor of the outcome evaluation.
In 2016, the US Food and Drug Administration (FDA) re-
classified transvaginal mesh for prolapse repair to a class III
device and required postmarket surveillance studies. In
February 2019, an FDA advisory panel concluded that to sup-
porta favorablebenefit/risk, surgicalmeshfor transvaginalpro-
lapse repair should be superior to native tissue repair at 36
months.35 In April 2019, the FDA announced that superiority
hadnotbeendemonstrated in thestudiesavailableat that time,
and thatmanufacturerswouldno longer bepermitted tomar-
ket transvaginal mesh kits for repair of anterior/apical com-
partmentprolapse.6Patients in thecurrent studyarebeing fol-
lowedup for 60months and the results and conclusions at 36
months could change with extended follow-up.
Trial strengths includetherandomizeddesign,maskedpar-
ticipants, validated anatomic and patient-reported out-
comes, and standardized adverse outcome collection. Three
years constitutes the longest duration of follow-up available
for a randomized clinical trial comparing mesh hysteropexy
with vaginal hysterectomy with uterosacral ligament pro-
lapse repair. Seventy-fivepercentofwomenremainedmasked
to their study procedure, and all patient-reported outcome
evaluatorsweremasked to surgical intervention.Becausepar-
ticipants or their evaluatorsmayhave certainbeliefs about the
presence or absence of a uterus, and because vaginal mesh is
controversial, masking decreased potential biases related to
Figure 2. Failure Probability for the Composite Primary Outcome
Comparing HysteropexyWith Hysterectomy inWomen
With Uterovaginal Prolapse
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Failure probability from survival analysis excluding the 8 ineligible participants
was conducted using an interval-censored proportional hazardmodel with an
assumed baseline piecewise exponential hazard with 4 constant hazard
periods: (0-12 months, 12-24months, 24-36months, and >36months) and
controlled for site consistent with study randomization as well as prior prolapse
surgery per clinical standards. Available follow-up data were included for all
participants through the time when the last participant reached 36months of
follow-up. At the time of analysis, 10 participants were censored prior to 36
months (7 in the hysteropexy group and 3 in the hysterectomy group), 50
participants were censored between 36 and 48months (27 in the
hysteropexy group and 23 in the hysterectomy group), and 50were censored
at or beyond 48months (27 in the hysteropexy group and 23 in the
hysterectomy group). Themedian (IQR) follow-up time was 36.0 (18.0-48.0)
months for the hysteropexy group and 36.0 (9.0-48.0) for the hysterectomy
group. The hazard rate in the hysteropexy group (incidence density per
person-year) in year 1 was 0.16; year 2, 0.07; year 3, 0.06; and beyond 3 years,
0.05. In the hysterectomy group, the hazard rate in year 1 was 0.26; year 2, 0.12;
year 3, 0.10; and beyond 3 years, 0.08. The failure probability from the
sensitivity nonparametric interval-censored Kaplan-Meier analysis is
represented by the dotted lines.23 The solid lines represent the piecewise
exponential model and the 95% CI for the piecewise exponential model is
shown by the blue shaded area for the hysterectomy group and the tan shaded
area for the hysteropexy group.
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hysterectomy or mesh and participants were potentially less
likely to be influenced by anti-mesh advertisements.
Limitations
This study has several limitations. First, generalizability may
be limited because many women had preconceived ideas
regarding hysterectomy, mesh, or randomization to a proce-
dure that they would be masked from knowing and declined
to participate. Second, to allow masking, the study was
restricted to postmenopausal women, and only 70 of 175 par-
ticipants (40%) were sexually active before surgery, limiting
the ability to evaluate postoperative sexual function and
Table 3. Categorization of Participants by Failure Categories at 12, 24, and 36Months in a Study of the Effect
of Vaginal Mesh Hysteropexy vs Vaginal Hysterectomy AmongWomenWith Uterovaginal Prolapse
Failure Outcomes
No. (%)
Risk Difference,
% (95% CI)a
Hysteropexy
(n = 88)a
Hysterectomy
(n = 87)a
Cumulative Failures (Time-to-Event)b
12-mo visit (n = 88) (n = 86)
Failure, No./total (%)b 15/86 (17) 22/85 (26) −8 (−21 to 4)
Initial failure type
Re-treatment 0 1 (1)
Anatomic and symptom failure 5 (6) 2 (2)
Anatomic failure only 9 (10) 17 (20)
Symptom failure only 1 (1) 2 (2)
24-mo visitb (n = 87) (n = 85)
Failure, No./total (%)b 21/80 (26) 29/83 (35) −9 (−24 to 5)
Initial failure type
Retreatment 0 1 (1)
Anatomic and symptom failure 7 (9) 3 (4)
Anatomic failure only 12 (15) 21 (25)
Symptom failure only 2 (3) 4 (5)
36-mo visitb (n = 86) (n = 85)
Failure, No./total (%)b 26/79 (33) 34/81 (42) −9 (−24 to 6)
Initial failure type
Re-treatment 0 1 (1)
Anatomic and symptom failure 9 (11) 6 (7)
Anatomic failure only 14 (18) 23 (28)
Symptom failure only 3 (4) 4 (5)
At-Visit Failures
12-mo visitc (n = 88) (n = 86)
Failure, No./total (%)b 12/86 (14) 19/84 (23) −9 (−21 to 3)
At-visit failure type
Re-treatment 2 (2) 2 (2)
Anatomic and symptom failure 3 (3) 4 (5)
Anatomic failure only 6 (7) 11 (13)
Symptom failure only 1 (1) 2 (2)
24-mo visitc (n = 87) (n = 84)
Failure, No./total (%)b 15/79 (19) 17/80 (21) −3 (−16 to 10)
At-visit failure type
Re-treatment 5 (6) 6 (8)
Anatomic and symptom failure 1 (1) 3 (4)
Anatomic failure only 7 (9) 6 (8)
Symptom failure only 2 (3) 2 (3)
36-mo visitc (n = 85) (n = 84)
Failure, No./total (%)b 16/78 (21) 21/78 (27) −6 (−19 to 7)
At-visit failure type
Re-treatment 5 (6) 9 (12)
Anatomic and symptom failure 4 (5) 1 (1)
Anatomic failure only 7 (9) 10 (13)
Symptom failure only 0 1 (1)
a All missing datawere considered to
bemissing completely at random
andwere excluded fromboth the
numerator and denominator in the
calculation of estimates and CIs.
Point estimates and 95%CIs for risk
difference in surgical failures
between the treatment groups are
based onMantel-Haenszel estimates
for the common risk difference
stratified by sitewithWald-type CIs
with the estimate of the variance of
the risk difference based on Sato.24
bUnder the permanent failure state
assumption, the number of
participants at each visit includes
all participantswhowere still
participating in the study or had a
failure outcomeprior towithdrawal.
The denominator for the cumulative
failure at each visit includes all
participantswhowere still
participating in the study and
attended the visit or had any failure
outcomeprior their withdrawal/
missed visit. The failure type
corresponding to the first failure time
is shown,where the 4 failure types
aremutually exclusive,with
re-treatment failure prioritized above
the anatomic and/or symptomatic
failure types.
c Under the transient failure state
assumption, thenumberof
participants at eachvisit includes all
participantswhowere still
participating in the study. The
denominator for the transient failures
at eachvisit includes all participants
whowere still participating in the
study andattended thevisit orwho
missed thevisit but hada
re-treatment failureprior to their
missedvisit. The failure type corre-
sponding to the failure at each time
point is shown,where the4 failure
types aremutually exclusive,with
re-treatment failureprioritized above
the anatomic and/or symptomatic
failure types andassumed tobea
permanent state at all subsequent
visits irrespectiveof theparticipant's
attendance at thevisit as long as the
participantwas still participating in
the study.Anatomic and symptom
failure components are considered to
be transient conditions, andwith
outcomes at each timepoint based
specifically onmeasurements
obtainedat that timepoint.
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dyspareunia. Pain and dyspareunia rates could be different
in younger patients. Third, all surgeons were female pelvic
medicine and reconstructive surgery subspecialists with
extensive surgical experience and results may not be gener-
alizable to surgical procedures performed by nonsubspecial-
ists or those without similar training. Fourth, 25% of partici-
pants were unmasked, which could have produced some
potential bias in patient-reported secondary outcomes.
Fifth, because the proportional hazard assumption was vio-
lated, the hazard ratio must be interpreted as an average
relative risk across time rather than a relative risk applicable
at each time.
Conclusions
Among women with symptomatic uterovaginal prolapse un-
dergoing vaginal surgery, vaginal mesh hysteropexy com-
paredwithvaginalhysterectomywithuterosacral ligamentsus-
pension did not result in a significantly lower rate of the
composite prolapse outcome after 3 years. However, impre-
cision in the study results precludes a definitive conclusion,
and further research isneeded toassesswhether vaginalmesh
hysteropexy ismore effective thanvaginal hysterectomywith
uterosacral ligament suspension.
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